ArticlePloS one2013
Combining genotype improvement and statistical media optimization for isoprenoid production in E. coli.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 65 citations in OpenAlex.
- Severe Restriction of Glucose Import Enhances Recombinant Protein Production in Escherichia coli.Biotechnology journal · 2026Article
- Fermentation design and process optimization strategy based on machine learning.Biodesign research · 2025Review
- Reconstitution of the Mevalonate Pathway for Improvement of Isoprenoid Production and Industrial Applicability inJournal of microbiology and biotechnology · 2024Article
- Article
- Amorpha-4,11-diene synthase: a key enzyme in artemisinin biosynthesis and engineering.aBIOTECH · 2021Review
- Carboxylesterases for the hydrolysis of acetoacetate esters and their applications in terpenoid production using Escherichia coli.Applied microbiology and biotechnology · 2021Article
- High-level de novo biosynthesis of glycosylated zeaxanthin and astaxanthin in Escherichia coli.Bioresources and bioprocessing · 2021Article
- Impact of culture condition modulation on the high-yield, high-specificity and cost-effective production of terpenoids from microbial sources: A review.Applied and environmental microbiology · 2021Review
- Construction of a Self-Purification and Self-Assembly Coenzyme Regeneration System for the Synthesis of Chiral Drug Intermediates.ACS omega · 2021Article
- Pathway Engineering Using Escherichia coli to Produce Commercialized Carotenoids.Advances in experimental medicine and biology · 2021Article
- Upcycling chitin-containing waste into organonitrogen chemicals via an integrated process.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Enhancing β-Carotene Production inFrontiers in bioengineering and biotechnology · 2020Article
- Metabolic perturbations in mutants of glucose transporters and their applications in metabolite production in Escherichia coli.Microbial cell factories · 2019Article
- Genome-Wide Association Study and Pathway-Level Analysis of Kernel Color in Maize.G3 (Bethesda, Md.) · 2019Article
- QbD Based Media Development for the Production of Fab Fragments inBioengineering (Basel, Switzerland) · 2019Article
- Multidimensional heuristic process for high-yield production of astaxanthin and fragrance molecules in Escherichia coli.Nature communications · 2018Article
- ConvertingProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Construction of a tunable multi-enzyme-coordinate expression system for biosynthesis of chiral drug intermediates.Scientific reports · 2016Article
- Artemisinin-based antimalarial research: application of biotechnology to the production of artemisinin, its mode of action, and the mechanism of resistance of Plasmodium parasites.Journal of natural medicines · 2016Review
- Lycopene overproduction in Saccharomyces cerevisiae through combining pathway engineering with host engineering.Microbial cell factories · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isoprenoids are a large and diverse class of compounds that includes many high value natural products and are thus in great demand. To meet the increasing demand for isoprenoid compounds, metabolic engineering of microbes has been used to produce isoprenoids in an economical and sustainable manner. To achieve high isoprenoid yields using this technology, the availability of metabolic precursors feeding the deoxyxylulose phosphate (DXP) pathway, responsible for isoprenoid biosynthesis, has to be optimized. In this study, phosphoenolpyruvate, a vital DXP pathway precursor, was enriched by deleting the genes encoding the carbohydrate phosphotransferase system (PTS) in E. coli. Production of lycopene (a C40 isoprenoid) was maximized by optimizing growth medium and culture conditions. In optimized conditions, the lycopene yield from PTS mutant was seven fold higher than that obtained from the wild type strain. This resulted in the highest reported specific yield of lycopene produced from the DXP pathway in E. coli to date (20,000 µg/g dry cell weight). Both the copy number of the plasmid encoding the lycopene biosynthetic genes and the expression were found to be increased in the optimized media. Deletion of PTS together with a similar optimization strategy was also successful in enhancing the production of amorpha-1,4-diene, a distinct C15 isoprenoid, suggesting that the approaches developed herein can be generally applied to optimize production of other isoprenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.